Innate Pharma

Thank you Leerink Partners for hosting us at the 2025 Global Healthcare Conference. We appreciated the opportunity to connect and exchange insights with such an engaged audience!   For those who couldn’t join us live, the replay is now available: https://lnkd.in/e8Dd4eyZ   Do not miss the chance to catch up on the key takeaways and updates!   #InnatePharma #IRmeeting #LeerinkPartners #HealthcareConference

🚀 L’immunothérapie avec les cellules NK : la prochaine révolution en oncologie ! 🧬 📅 Le 11 mars 2025 à 10h30, Eric Vivier, Directeur Scientifique d’Innate Pharma, présentera les dernières avancées en immunothérapie avec les cellules NK lors de l’événement ICE 360° à Paris. 🔬 Découvrez comment ces cellules naturelles peuvent transformer le traitement du cancer ! #InnatePharma #ICE360Congress #Immunotherapy #CellulesNK #Oncologie #Innovation

We are pleased to present the preclinical characterization of our Nectin-4 targeting ADC, IPH4502, during a poster session at the #WorldADC Congress being held from March 3 - 6, 2025. 📍 ➡️ IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4 ➡️ IPH4502  demonstrates anti-tumor activity in tumors with a broad range of Nectin-4 expression, supporting its development beyond urothelial carcinoma ➡️ The 1st patient in the Phase 1 study (NCT06781983) was dosed in January 2025  More info: https://lnkd.in/eVkYdzm #WorldADC #ADC #AntibodyDrugConjugates

Merci à Laurent Grassin pour son invitation au Journal des Biotech de BOURSORAMA 🎥 Cet échange était l’occasion pour Jonathan Dickinson de présenter son parcours et faire un bilan de ses premiers mois en tant que nouveau Président du Directoire d’Innate Pharma, mais également de revenir sur les dernières actualités de la société, notamment la nouvelle stratégie de croissance, les orientations stratégiques pour 2025 et l’obtention du statut « Breakthrough Therapy » pour lacutamab. ⏯️ Retrouvez le replay du Journal des Biotechs (18:00) : https://lnkd.in/eCWyjjT9 #InnatePharma #Journaldesbiotechs #Boursorama

#MeetInnate Our management will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held on March 10-12, 2025 in Miami Florida. 🤝📍 🎙️ The management team will represent the Company in a session scheduled Tuesday, March 11, 2025, from 3:00 - 3:30 pm ET. A live webcast and a replay of the presentation will be available on the following link: https://lnkd.in/e8Dd4eyZ #InnatePharma #LeerinkPartners #IRmeeting #Investor

🔬 Meet Eric Vivier, Scientific Director of Innate Pharma, who will be speaker at ESMO TAT 2025 on March 5, during an educational session to highlight the potential of NK cells in cancer treatment. More information on the program 👉 https://lnkd.in/eMapVrrV #InnatePharma #ESMOTAT2025 #Immunotherapy #NKcell ESMO - European Society for Medical Oncology

Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary syndrome 🚀 ➡️ Designation is based on TELLOMAK Phase 2 results ➡️ Breakthrough Therapy Designation is intended to accelerate the development and regulatory review in the U.S. of drugs that are intended to treat a serious condition A key step in Innate Pharma's development of therapeutic solutions to beat cancer! For more info, read the press release: https://lnkd.in/etBsE7TC #InnatePharma #FDA #BreakthroughTherapyDesignation

🌍In celebration of the International Day of Women and Girls in Science, we want to honor the vital role that women play in the scientific field. At Innate Pharma, we firmly believe that diversity is a driving force for innovation. 🔬Watch the video below to discover Caroline’s history and how she is contributing to Innate Pharma’s mission to offer a better future for patients. The journey of women in science is a true driver of progress. We are proud to support our talents and actively contribute to reducing gender inequality in science. #WomenInScience #InternationalDayOfWomenAndGirlsInScience #ImmunoOncology #Innovation #Diversity #Biotech #CancerResearch 

We were pleased to welcome investors and analysts to our event dedicated to our antibody-drug conjugate strategy and our lead ADC program, IPH4502. 👥🧬 Many thanks to the participants and to Dr. Yohann Loriot from Institut Gustave Roussy for his educational presentation on the environment of ADCs developed in solid tumors. ➡️ Click on the following link to watch the replay of the presentation: https://lnkd.in/esKcqRTF #InnatePharma #AntibodyDrugConjugate #Immunotherapy

Nos équipes sont engagées aux côtés du Paris Saclay Cancer Cluster (PSCC) lors du PSCC Innovation Forum ! Un grand merci à Eric Vivier et Olivier Demaria d'avoir brillamment représenté Innate Pharma.